NASDAQ:MNLO - Menlo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.00 -0.06 (-0.66 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$9.06
Today's Range$8.90 - $9.21
52-Week Range$6.99 - $39.86
Volume57,000 shs
Average Volume155,827 shs
Market Capitalization$208.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics logoMenlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNLO
CUSIPN/A
Phone650-486-1416

Debt

Debt-to-Equity RatioN/A
Current Ratio18.85
Quick Ratio18.85

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.58 million
Price / Sales45.16
Cash FlowN/A
Price / CashN/A
Book Value$7.21 per share
Price / Book1.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees32
Outstanding Shares22,980,000

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics (NASDAQ:MNLO) posted its earnings results on Wednesday, May, 9th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The business earned $0.50 million during the quarter, compared to the consensus estimate of $0.56 million. View Menlo Therapeutics' Earnings History.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Menlo Therapeutics.

What price target have analysts set for MNLO?

4 Wall Street analysts have issued 12-month price objectives for Menlo Therapeutics' shares. Their forecasts range from $11.00 to $48.00. On average, they anticipate Menlo Therapeutics' share price to reach $36.00 in the next year. View Analyst Ratings for Menlo Therapeutics.

Are investors shorting Menlo Therapeutics?

Menlo Therapeutics saw a drop in short interest in April. As of April 13th, there was short interest totalling 488,484 shares, a drop of 38.6% from the March 30th total of 795,809 shares. Based on an average trading volume of 604,603 shares, the short-interest ratio is presently 0.8 days. Approximately 4.4% of the company's shares are short sold.

Who are some of Menlo Therapeutics' key competitors?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 52)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 46)
  • Dr. Paul S. Kwon M.D., Chief Medical Officer
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 53)
  • Dr. Xiaoming Zhang Ph.D., Sr. VP of Non-Clinical & Pharmaceutical Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an initial public offering on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and JMP Securities was co-manager.

Has Menlo Therapeutics been receiving favorable news coverage?

Media headlines about MNLO stock have been trending somewhat positive on Saturday, Accern reports. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Menlo Therapeutics earned a news sentiment score of 0.11 on Accern's scale. They also assigned news stories about the company an impact score of 45.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.99%), VHCP Management II LLC (1.48%), Rock Springs Capital Management LP (1.44%), Franklin Resources Inc. (0.87%), JPMorgan Chase & Co. (0.50%) and Nexthera Capital LP (0.32%). View Institutional Ownership Trends for Menlo Therapeutics.

Which institutional investors are buying Menlo Therapeutics stock?

MNLO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., VHCP Management II LLC, Rock Springs Capital Management LP, Franklin Resources Inc., JPMorgan Chase & Co., Nexthera Capital LP, Northern Trust Corp and Landscape Capital Management L.L.C.. View Insider Buying and Selling for Menlo Therapeutics.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $9.00.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $208.18 million and generates $4.58 million in revenue each year. The company earns $-29,070,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Menlo Therapeutics employs 32 workers across the globe.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]


MarketBeat Community Rating for Menlo Therapeutics (MNLO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  31
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Menlo Therapeutics (NASDAQ:MNLO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Menlo Therapeutics in the last 12 months. Their average twelve-month price target is $36.00, suggesting that the stock has a possible upside of 300.00%. The high price target for MNLO is $48.00 and the low price target for MNLO is $11.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.752.753.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $36.00$36.00$46.25N/A
Price Target Upside: 300.00% upside349.44% upside32.60% upsideN/A

Menlo Therapeutics (NASDAQ:MNLO) Consensus Price Target History

Price Target History for Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (NASDAQ:MNLO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2018GuggenheimReiterated RatingBuy$11.00HighView Rating Details
4/9/2018Jefferies GroupDowngradeBuy ➝ HoldN/AView Rating Details
2/20/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$44.00 ➝ $44.00HighView Rating Details
2/20/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$48.00HighView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Menlo Therapeutics (NASDAQ:MNLO) Earnings History and Estimates Chart

Earnings by Quarter for Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (NASDAQ:MNLO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.76)($0.76)($0.76)
Q3 20181($0.80)($0.80)($0.80)
Q4 20181($0.74)($0.74)($0.74)

Menlo Therapeutics (NASDAQ MNLO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/9/2018Q1 2018($0.6650)($0.72)$0.56 million$0.50 millionViewN/AView Earnings Details
3/28/2018Q4($0.6870)($1.80)$2.78 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Menlo Therapeutics (NASDAQ:MNLO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Menlo Therapeutics (NASDAQ MNLO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 65.67%
Insider Trading History for Menlo Therapeutics (NASDAQ:MNLO)
Institutional Ownership by Quarter for Menlo Therapeutics (NASDAQ:MNLO)

Menlo Therapeutics (NASDAQ MNLO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2018Vivo Capital Surplus Fund ViiiMajor ShareholderBuy294,118$17.00$5,000,006.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Menlo Therapeutics (NASDAQ MNLO) News Headlines

Source:
DateHeadline
 Analysts Set $32.25 Price Target for Menlo Therapeutics (MNLO) Analysts Set $32.25 Price Target for Menlo Therapeutics (MNLO)
www.americanbankingnews.com - May 23 at 9:18 PM
NEA Promotes Carmen Chang and Ali Behbahani to General PartnerNEA Promotes Carmen Chang and Ali Behbahani to General Partner
www.bizjournals.com - May 23 at 9:22 AM
Reviewing Menlo Therapeutics (MNLO) and Its CompetitorsReviewing Menlo Therapeutics (MNLO) and Its Competitors
www.americanbankingnews.com - May 22 at 9:06 AM
Results Presented at the International Investigative Dermatology MeetingResults Presented at the International Investigative Dermatology Meeting
globenewswire.com - May 21 at 8:51 AM
Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant TreatmentStanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatment
finance.yahoo.com - May 21 at 8:51 AM
Head-To-Head Comparison: Menlo Therapeutics (MNLO) vs. The CompetitionHead-To-Head Comparison: Menlo Therapeutics (MNLO) vs. The Competition
www.americanbankingnews.com - May 20 at 1:35 PM
 Analysts Anticipate Menlo Therapeutics (MNLO) Will Post Quarterly Sales of $1.31 Million Analysts Anticipate Menlo Therapeutics (MNLO) Will Post Quarterly Sales of $1.31 Million
www.americanbankingnews.com - May 19 at 5:25 AM
Geron Announces Oral Presentation at European Hematology Association CongressGeron Announces Oral Presentation at European Hematology Association Congress
www.nasdaq.com - May 17 at 3:24 PM
-$0.84 EPS Expected for Menlo Therapeutics (MNLO) This Quarter-$0.84 EPS Expected for Menlo Therapeutics (MNLO) This Quarter
www.americanbankingnews.com - May 17 at 1:25 AM
Reviewing Menlo Therapeutics (MNLO) & Verona Pharma (VRNA)Reviewing Menlo Therapeutics (MNLO) & Verona Pharma (VRNA)
www.americanbankingnews.com - May 14 at 11:05 AM
Menlo Therapeutics (MNLO) Issues Quarterly  Earnings Results, Misses Estimates By $0.06 EPSMenlo Therapeutics (MNLO) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 11 at 11:14 PM
Contrasting Menlo Therapeutics (MNLO) & The CompetitionContrasting Menlo Therapeutics (MNLO) & The Competition
www.americanbankingnews.com - May 11 at 11:25 AM
Transcriptic Appoints Life Science Industry Veteran Jeff Finer, M.D., Ph.D. to Board of DirectorsTranscriptic Appoints Life Science Industry Veteran Jeff Finer, M.D., Ph.D. to Board of Directors
www.businesswire.com - May 10 at 8:40 AM
Menlo Therapeutics misses by $0.05, beats on revenueMenlo Therapeutics misses by $0.05, beats on revenue
seekingalpha.com - May 10 at 8:40 AM
BRIEF-Menlo Therapeutics Reports Qtrly Loss Per Share $0.72BRIEF-Menlo Therapeutics Reports Qtrly Loss Per Share $0.72
www.reuters.com - May 10 at 8:40 AM
Menlo Therapeutics Reports First Quarter 2018 Financial ResultsMenlo Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 8:40 AM
Brokerages Anticipate Menlo Therapeutics (MNLO) to Announce ($0.68) Earnings Per ShareBrokerages Anticipate Menlo Therapeutics (MNLO) to Announce ($0.68) Earnings Per Share
www.americanbankingnews.com - May 8 at 11:43 AM
Blue Mesa Health Inc. Accepted into Prestigious Metabridge and C100 48 Hours in the Valley ProgramsBlue Mesa Health Inc. Accepted into Prestigious Metabridge and C100 48 Hours in the Valley Programs
www.bizjournals.com - May 7 at 3:24 PM
Menlo Therapeutics Announces Senior Clinical Leadership UpdatesMenlo Therapeutics Announces Senior Clinical Leadership Updates
finance.yahoo.com - May 7 at 8:37 AM
Head-To-Head Review: Menlo Therapeutics (MNLO) versus Its PeersHead-To-Head Review: Menlo Therapeutics (MNLO) versus Its Peers
www.americanbankingnews.com - May 4 at 3:22 AM
Menlo Therapeutics (MNLO) Upgraded to "Hold" by ValuEngineMenlo Therapeutics (MNLO) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM
$560,000.00 in Sales Expected for Menlo Therapeutics (MNLO) This Quarter$560,000.00 in Sales Expected for Menlo Therapeutics (MNLO) This Quarter
www.americanbankingnews.com - May 1 at 2:58 AM
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology OfficerAdicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
www.bizjournals.com - April 30 at 8:40 AM
 Analysts Expect Menlo Therapeutics (MNLO) to Post -$0.68 Earnings Per Share Analysts Expect Menlo Therapeutics (MNLO) to Post -$0.68 Earnings Per Share
www.americanbankingnews.com - April 29 at 11:12 AM
Menlo Therapeutics (MNLO) Short Interest UpdateMenlo Therapeutics (MNLO) Short Interest Update
www.americanbankingnews.com - April 29 at 2:44 AM
Menlo Therapeutics (MNLO) Earns "Buy" Rating from GuggenheimMenlo Therapeutics (MNLO) Earns "Buy" Rating from Guggenheim
www.americanbankingnews.com - April 25 at 8:24 AM
After-Hours Stock Movers 04/24: (VICR) (MNKD) (CREE) Higher; (TER) (MNLO) (EW) Lower (more...)After-Hours Stock Movers 04/24: (VICR) (MNKD) (CREE) Higher; (TER) (MNLO) (EW) Lower (more...)
www.streetinsider.com - April 25 at 8:23 AM
BRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant HaltedBRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted
www.reuters.com - April 25 at 8:23 AM
 Menlo Therapeutics (MNLO) Given Average Rating of "Buy" by Analysts Menlo Therapeutics (MNLO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 23 at 5:29 AM
Head-To-Head Contrast: Menlo Therapeutics (MNLO) and Hutchison China MediTech (HCM)Head-To-Head Contrast: Menlo Therapeutics (MNLO) and Hutchison China MediTech (HCM)
www.americanbankingnews.com - April 20 at 5:11 PM
Detailed Research: Economic Perspectives on Menlo Therapeutics, Potbelly ...Detailed Research: Economic Perspectives on Menlo Therapeutics, Potbelly ...
globenewswire.com - April 18 at 3:24 PM
6 Biotech and Medtech Stocks That Saw Massive Moves Last Week6 Biotech and Medtech Stocks That Saw Massive Moves Last Week
247wallst.com - April 16 at 8:07 AM
Menlo Crashes On Failed Phase 2 Atopic Dermatitis Study, A Great Buying Opportunity?Menlo Crashes On Failed Phase 2 Atopic Dermatitis Study, A Great Buying Opportunity?
seekingalpha.com - April 16 at 8:07 AM
 Analysts Anticipate Menlo Therapeutics (MNLO) Will Announce Quarterly Sales of $560,000.00 Analysts Anticipate Menlo Therapeutics (MNLO) Will Announce Quarterly Sales of $560,000.00
www.americanbankingnews.com - April 14 at 2:56 AM
-$0.68 EPS Expected for Menlo Therapeutics (MNLO) This Quarter-$0.68 EPS Expected for Menlo Therapeutics (MNLO) This Quarter
www.americanbankingnews.com - April 12 at 1:24 PM
FY2019 EPS Estimates for Menlo Therapeutics (MNLO) Boosted by Jefferies GroupFY2019 EPS Estimates for Menlo Therapeutics (MNLO) Boosted by Jefferies Group
www.americanbankingnews.com - April 11 at 9:17 AM
Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%
seekingalpha.com - April 10 at 7:39 AM
Is Menlo Therapeutics A Discount Opportunity At Current Pricing?Is Menlo Therapeutics A Discount Opportunity At Current Pricing?
finance.yahoo.com - April 10 at 7:39 AM
Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares SlideMid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide
www.nasdaq.com - April 9 at 3:21 PM
Menlo Therapeutics Inc. (MNLO) Is Sinking After Phase 2 Study FailsMenlo Therapeutics Inc. (MNLO) Is Sinking After Phase 2 Study Fails
www.nasdaq.com - April 9 at 3:21 PM
Menlo Therapeutics lead candidate flunks mid-stage study; shares down 55% premarketMenlo Therapeutics' lead candidate flunks mid-stage study; shares down 55% premarket
seekingalpha.com - April 9 at 3:21 PM
First-quarter IPO star Menlo Therapeutics plummets on disappointing trial resultsFirst-quarter IPO star Menlo Therapeutics plummets on disappointing trial results
www.bizjournals.com - April 9 at 3:21 PM
Menlo Therapeutics (MNLO) Downgraded to "Hold" at Jefferies GroupMenlo Therapeutics (MNLO) Downgraded to "Hold" at Jefferies Group
www.americanbankingnews.com - April 9 at 8:25 AM
Menlo Therapeutics stock plunges over 50% after disappointing trial resultsMenlo Therapeutics' stock plunges over 50% after disappointing trial results
www.marketwatch.com - April 9 at 7:58 AM
 Menlo Therapeutics (MNLO) Given $46.25 Consensus Target Price by Analysts Menlo Therapeutics (MNLO) Given $46.25 Consensus Target Price by Analysts
www.americanbankingnews.com - April 8 at 7:28 AM
Menlo Therapeutics (MNLO) Announces Quarterly  Earnings Results, Misses Expectations By $1.11 EPSMenlo Therapeutics (MNLO) Announces Quarterly Earnings Results, Misses Expectations By $1.11 EPS
www.americanbankingnews.com - March 29 at 2:21 PM
Menlo Therapeutics misses by $1.11, beats on revenueMenlo Therapeutics misses by $1.11, beats on revenue
seekingalpha.com - March 29 at 7:37 AM
Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsMenlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 29 at 7:37 AM
Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent PropertiesPraxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties
globenewswire.com - March 28 at 3:20 PM
Menlo Therapeutics Inc (MNLO) to Post FY2021 Earnings of ($2.61) Per Share, Piper Jaffray ForecastsMenlo Therapeutics Inc (MNLO) to Post FY2021 Earnings of ($2.61) Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - March 28 at 7:10 AM

SEC Filings

Menlo Therapeutics (NASDAQ:MNLO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Menlo Therapeutics (NASDAQ MNLO) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.